About US
Contact us
-
As Sandoz contract winds down, GSK will close antibiotics plant in UKWith the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing facility in its home country. The U.K. pharma will close its plant in Ulvers2024/8/27
-
Lilly looks inward as it completes hunt for new CFO with appointment of 23-year vet Lucas MontarceThree months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO, Anat Ashkenazi, the company didn’t have to look far. Lilly on Mondayreve2024/8/22
-
AstraZeneca's Alexion loses $130M to Syntimmune shareholders in post-merger payment suitWhen AstraZeneca’s Alexionpicked uprare disease specialist Syntimmune in 2018 for $400 million, the latter’s FcRn inhibitor dubbed SYNT001 was the crown jewel of the deal. After Alexion scrapped its2024/8/22
-
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancerThe Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibo2024/8/20
-
J&J bolsters Rybrevant-Lazcluze's case against AZ's Tagrisso with survival analysisJohnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better challen2024/8/20
-
GSK posts COPD win for Nucala as Sanofi-Regeneron rival Dupixent nears delayed FDA decisionGSK is heading into the weekend with a win for its respiratory blockbuster Nucala—but for now, the details are slim. On Friday, GSK said that its IL-5 antibody Nucala plus inhaled maintenance therapy2024/8/15
-
Fierce Pharma Asia—Astellas' plant closure, lab debut; China's probe into AstraZeneca staffersAstellas is closing a gene therapy manufacturing facility in South San Francisco. But, across the country, the company opened a new R&D center in Massachusetts. Chinese authorities detained sever2024/8/15
-
Despite trial scare, Travere's Filspari gains full FDA nod in kidney disease showdown with NovartisA year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. The FDA has converted Filspari’s conditional nod in the kidney disease IgA nephropathy (IgAN) into a full a2024/8/13
-
BIOSECURE Act heads for possible vote in House of Representatives next weekAfter running up against a roadblock earlier this summer, the controversial BIOSECURE Act could gain new momentum next week. The U.S. House of Representatives isslated to considerthe legislation duri2024/8/13
-
Bayer's Kerendia passes key test, cutting risk of cardio death and heart failureBayer’s Kerendia was approved in 2021 to treat patients with chronic kidney disease (CKD) associated with Type 2 diabetes. For the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) to accomp2024/8/8